Pharmacokinetics of pertuzumab biosimilar compared with the original drug in cynomolgus monkeys

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

BACKGROUND: Developing biosimilar monoclonal antibodies for treating malignant diseases is a critical task. RPH-051 (pertuzumab) is a biosimilar drug, a recombinant humanized monoclonal antibody targeting type 2 human epidermal growth factor receptors. At the stage of non-clinical development, studies of pharmacokinetics of biosimilar vs. original drug product in a relevant animal species, provide important information on the comparability of drugs.

AIM: To evaluate the pharmacokinetics of the biosimilar product RPH-051 in comparison with the original drug after a single intravenous injection in a cynomolgus monkey model.

MATERIALS AND METHODS: The study was conducted in 8 cynomolgus monkeys (Macaca fascicularis) divided into 2 groups, each including 2 females and 2 males. The first group received the biosimilar RPH-051 (international nonproprietary name is pertuzumab, AO R-Pharm, Russia), the second group was treated with the comparator Perjeta® (international nonproprietary name is pertuzumab). The drugs were administered as a single intravenous dose of 50 mg/kg. Blood samples were collected before dosing, then at 1 min, 1, 2, 4, 8, 24 h, and on days 3, 7, 10, 14, 21 and 28 post-dosing. Quantitative analysis of pertuzumab serum levels was performed using enzyme-linked immunosorbent assay (ELISA) with spectrophotometric detection in the visible range of the spectrum.

RESULTS: The method of quantitative assessment of serum level of pertuzumab using (ELISA) in cynomolgus monkeys was developed. The method was validated against the following parameters: selectivity, minimum required dilution, lower limit of quantification, calibration range, accuracy and precision (within the analytical run and between runs), specificity, linearity (possibility) of sample dilution, parallelism, and stability of the analyte in serum.

Comparability of the drugs in the main pharmacokinetic parameters was established. The mean Cmax and AUClast values of RPH-051 and of the comparator were 1684.34 and 1405.34 μg/mL (Cmax); 265,282.18 and 280,168.92 (μg/mL)×h (AUClast), respectively.

CONCLUSION: Comparability between the pharmacokinetic profiles of the biosimilar RPH-051 and the originator’s drug was demonstrated. In the course of the study, no adverse clinical events, animal body weight changes, or injection site reactions associated with the tested drugs were observed.

Full Text

Restricted Access

About the authors

Anna I. Podolyakina

Joint-Stock Company "R-Pharm"

Author for correspondence.
Email: podolyakina@rpharm.ru
ORCID iD: 0009-0002-5602-7926
Russian Federation, Moscow

Anastasia A. Dmitrieva

Joint-Stock Company "R-Pharm"

Email: aa.dmitrieva@rpharm.ru
ORCID iD: 0000-0003-4743-6189
Russian Federation, Moscow

Victoria A. Postnikova

Limited Liability Company "Research Lab"

Email: v.postnikova@researchlab.ru
ORCID iD: 0009-0007-7505-5734
Russian Federation, Moscow

Anastasia A. Konstantinova

Limited Liability Company "Research Lab"

Email: a.konstantinova@researchlab.ru
ORCID iD: 0009-0007-7077-3630
Russian Federation, Moscow

Anna V. Petkova

Joint-Stock Company "R-Pharm"

Email: zinkovskaya@rpharm.ru
ORCID iD: 0000-0002-7028-0496
Russian Federation, Moscow

Alexander P. Trashkov

Kurchatov Institute

Email: trashkov_ap@nrcki.ru
ORCID iD: 0000-0002-3441-0388
SPIN-code: 4231-1258

MD, Cand. Sci. (Medicine)

Russian Federation, Moscow

Olga A. Shamsutdinova

Kurchatov Institute

Email: shamsutdinova-o-a@yandex.ru
ORCID iD: 0000-0002-2742-3965
SPIN-code: 6827-2067

Cand. Sci. (Biology)

Russian Federation, Moscow

Daria A. Terenteva

Joint-Stock Company "R-Pharm"

Email: da.terenteva@rpharm.ru
ORCID iD: 0009-0000-3298-4815
Russian Federation, Moscow

Elizaveta Dubatovka

Joint-Stock Company "R-Pharm"

Email: dubatovka@rpharm.ru
ORCID iD: 0009-0003-6074-5290
Russian Federation, Moscow

Elena V. Shipaeva

Joint-Stock Company "R-Pharm"

Email: shipaeva@rpharm.ru
ORCID iD: 0000-0002-5953-984X

MD, Cand. Sci. (Medicine)

Russian Federation, Moscow

Olga V. Filon

Joint-Stock Company "R-Pharm"

Email: ov.filon@rpharm.ru
ORCID iD: 0000-0002-8735-7429
Russian Federation, Moscow

Mikhail Yu. Samsonov

Joint-Stock Company "R-Pharm"

Email: samsonov@r-pharm.com
ORCID iD: 0000-0003-2685-1623

MD, Cand. Sci. (Medicine)

Russian Federation, Moscow

Vasily G. Ignatiev

Joint-Stock Company "R-Pharm"

Email: ignatiev@rpharm.ru
ORCID iD: 0000-0003-2818-6583
SPIN-code: 4991-2286

MD, Cand. Sci. (Medicine)

Russian Federation, Moscow

References

  1. New Russian biosimilars and generics against cancer occupied 60% of the entire clinical research market in Russia. Scientific and Production Journal of Drug Development and Registration [Internet]. [cited 2024 Sep 17]. Available from: https://www.pharmjournal.ru/jour/announcement/view/1442.
  2. Giri M, Giri M, Thapa RJ, et al. Breast Cancer in Nepal: Current Status and Future Directions. Biomedical Reports. 2018; 8(4);325–329.
  3. Trapani D, Ginsburg O, Fadelu T. et al. Global challenges and policy solutions in breast cancer control. Cancer Treatment Reviews. 2022; 104
  4. Frolova MA. Neoadjuvant systemic therapy of HER2-positive breast cancer. Journal of Modern Oncology. 2015;17(4):22–25.
  5. Cross-Discipline team leader review; Center for Drug Evaluation and Research [Internet]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/125409Orig1s000CrossR.pdf
  6. Volskaya E. Biosimilars: regulations specificity. Remedium. 2011;3:10–12. Available from: https://cyberleninka.ru/article/n/biosimilyary-osobennosti-regulyatornyh-norm
  7. Eltcova EA, Ramenskaya GV, Smolyarchuk EA, Bushmanova AV. Biosimilars — drugs of the future. Pharmacokinetics and Pharmacodynamics. 2015;(1):12–15. EDN: UCDSXN
  8. Niyazov RR, Dranitsyna MA, Vasiliev AN, Gavrishina EV. Biosimilars: development and investigation using achievements in modern biotechnology. Diabetes mellitus. 2020;23(6):548–560. EDN: MSIKHJ doi: 10.14341/DM12576
  9. Ishii-Watabe A, Kuwabara T. Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies. Drug Metabolism and Pharmacokinetics. 2019;34(1):64–70. doi: 10.1016/j.dmpk.2018.11.004
  10. Kwon O, Joung J, Park Y, et al. Considerations of critical quality attributes in the analytical comparability assessment of biosimilar products. Biologicals. 2017;48:101–108. doi: 10.1016/j.biologicals.2017.04.005
  11. Al-Sabbagh A, Olech E, McClellan JE, Kirchhoff CF. Development of biosimilars. Seminars in Arthritis Rheumatism. 2016;45(5):11–18.
  12. Mahmood I, Green MD. Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins. Clinical Pharmacokinetics. 2005;44(4):331–347. doi: 10.2165/00003088-200544040-00001
  13. Chapman K, Adjei A, Baldrick P, et al. Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challenges. MAbs. 2016;8(3):427–435. doi: 10.1080/19420862.2016.1145331
  14. Webster C, Wong A, Woollett G. An Efficient Development Paradigm for Biosimilars. BioDrugs. 2019;33(6):603–611. doi: 10.1007/s40259-019-00371-4
  15. Van Meer PJ, Kooijman M, Van der Laan JW, et al. The value of non-human primates in the development of monoclonal antibodies. Nature Biotechnology. 2013;31(10):882–883. doi: 10.1038/nbt.2709
  16. Van Aerts L, De Smet K, Reichmann G, et al. Biosimilars entering the clinic without animal studies. mAbs. 2014;6(5):1155–1162. doi: 10.4161/mabs.29848
  17. Center for Drug Evaluation and Research. Pharmacology review(s). Perjeta (pertuzumab) [Internet]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/
  18. Samsonov MYu, Dmitrieva AA, Konopleva GE, et al. Nonclinical studies of biotechnology derived products – theory and practice specificity. Medical Journal of the Russian Federation. 2018;24(6):324–331. EDN: YYFOWL doi: 10.18821/0869-2106-2018-24-6-324-331

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. 1. An example of a typical calibration dependence of optical density on the concentration of RPH-051 (pertuzumab) in blood serum obtained during validation.

Download (332KB)
3. Fig. 2. Dynamics of pertuzumab concentrations (mean±95% CI) after administration of RPH-051 (n=3) and reference drug (n=4).

Download (185KB)

Copyright (c) 2024 Eco-Vector



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС 77 - 86496 от 11.12.2023 г
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ЭЛ № ФС 77 - 80673 от 23.03.2021 г
.